Elevated Non-HDL Cholesterol Is Associated with Greater Cardiovascular Risk

And lowering non-HDL-c has the potential to lower that risk, with the greatest benefit in young people.

Atherogenic (apolipoprotein-B containing) lipoproteins mediate the association of hypercholesterolemia with cardiovascular disease (CVD). Measurement of non-HDL cholesterol (non-HDL-c) to capture the total amount of atherogenic lipoproteins is simple and clinically available. To evaluate the effects of elevated non-HDL-c on a first CV event (coronary heart disease event or ischemic stroke) investigators analyzed data from the Multinational Cardiovascular Risk Consortium (38 cohorts from North America, Europe, and Australia).

Participants with prior CVD were excluded. Over a maximum follow-up of 44 years in 398,846 individuals (median age, 51; 49% women), 54,542 CV events occurred. Higher non-HDL-c was associated with higher CV event rates, a…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)